David Theis, MD
Rheumatology · Colorado Springs, CONPI 1104147453
Payments from drug & device makers
Across 781 payments — averaging $78.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$24K
- Novartis$21K
- Amgen$9K
- UCB, Inc.$1K
- AstraZeneca$1K
- Pfizer$844
- plus $3K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 241 | $24,227 |
| Novartis | 68 | $21,475 |
| Amgen(2 entities) | 140 | $8,985 |
| UCB, Inc. | 52 | $1,119 |
| AstraZeneca(2 entities) | 48 | $1,038 |
| Pfizer | 64 | $844 |
| GSK | 40 | $547 |
| Johnson & Johnson | 16 | $381 |
| Sobi, Inc | 13 | $349 |
| Sandoz | 12 | $317 |
| Genentech USA, Inc. | 12 | $188 |
| Lilly USA, LLC | 9 | $185 |
| ANI Pharmaceuticals, Inc. | 14 | $182 |
| Actelion Pharmaceuticals US, Inc. | 5 | $122 |
| Mallinckrodt Hospital Products Inc. | 5 | $122 |
| Celltrion USA Inc. | 4 | $104 |
| E.r. Squibb & Sons, L.L.C. | 6 | $101 |
| Boehringer Ingelheim | 4 | $96 |
| Radius Health, Inc. | 4 | $88 |
| Scilex Pharmaceuticals Inc. | 4 | $65 |
| Octapharma USA, Inc. | 3 | $62 |
| Fresenius Kabi USA, LLC | 2 | $44 |
| Kyowa Kirin, Inc. | 2 | $42 |
| Ferring Pharmaceuticals Inc. | 2 | $33 |
| Mallinckrodt Enterprises LLC | 2 | $32 |
| Sanofi | 2 | $31 |
| Biocon Biologics Inc | 1 | $25 |
| Organon | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Mylan Institutional Inc. | 1 | $23 |
| Aurinia Pharma U.S., Inc. | 1 | $18 |
| Gilead | 1 | $17 |
| Merck | 1 | $15 |
How this compares
$60,923 in reported general payments places this provider in the 80th percentile of 108 rheumatology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Colorado Springs
- Michael SayersColorado Springs$71K
- Christopher ChongColorado Springs$11K
- Artur KalutaColorado Springs$7K
- Megan MacneilColorado Springs$6K
- Christopher InserraColorado Springs$5K
- Dan CristescuColorado Springs$4K
- Michael ThakorFort Collins$7.3M
- Christopher AntoliniDenver$6.9M
- Christopher StriebichAurora$2M
- Larry MorelandAurora$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.